News & Events

COVID-19 Has a Far-Reaching Impact on Cancer Patients

The COVID-19 pandemic has presented challenges both to the medical system overall and to the ongoing treatment of patients with cancer. Patients are experiencing delays in care, additional financial strains, and mental health challenges in the current environment. To measure the impact of the COVID-19 pandemic on cancer patients, the American Cancer Society Cancer Action Network conducted online surveys in March and early May that included >1200 cancer patients and survivors (margin of error ±3% and 96% CI), 111 caregivers, and 139 healthcare providers. The patients who responded had various cancers, with breast cancer being the most prevalent (51%), and a variety of different insurance types, with employer-provided insurance most common (55%).

Early diagnosis and treatment are the cornerstones of effective therapy for aggressive cancers. In March, more than half of the cancer patients surveyed reported disruptions to their health care, and this increased to 87% in the early May survey. Of those in active treatment in early May, 78% reported delays to their care (vs 24% in the March survey), with 17% reporting delays to cancer therapy (eg, chemotherapy, radiation, endocrine therapy) and 25% reporting delays in imaging. Many of these delays were more than 2 weeks, and imaging services were often postponed with no known timing for rescheduling. These delays in important diagnostic and interventional procedures could provide an additional source of stress for patients and compromise outcomes.

In addition to the challenge of delayed care, the pandemic has decreased economic stability. Some patients may have difficulty paying for care or accessing the care they need due to loss of jobs and insurance coverage. Nearly half (46%) of the patients surveyed said COVID-19 impacted their financial situation and ability to pay for care (up from 38% in March). Approximately 1 in 4 of the respondents worried about loss of health insurance. Financial concerns were not limited to healthcare costs, as many patients reported worrying about paying for basic household expenses like rent or mortgage, utilities, and food. Although this was more common among the lowest-income bracket (54% of respondents with ≤$30,000 annual household income), worry about these expenses was prevalent across all income brackets, including in 20% of respondents with ≥$110,000 annual household income.

Combined medical and financial stresses led nearly half (48%) of the respondents to report that the pandemic has had a moderate or major effect on their mental health. Possibly contributing to this anxiety, 70% of the patients with cancer reported challenges in obtaining personal protective equipment. Relaxation of social distancing measures has also increased stress and anxiety; 67% worry about their safety as communities reopen. This concern was especially prevalent among minority respondents (76%).

Healthcare providers and caregivers similarly reported concern about delayed care and providing support for patients in the context of public health restrictions. Caregivers, like patients, reported anxiety over reopening and the increased potential that they or their loved ones could be exposed to the virus.

High Altitude: In this unprecedented time, weighing the benefit vs risk of visits to the clinic or hospital for treatments and imaging studies is difficult both for physicians and patients. Patients are aware that disruptions and delays in care have potential long-term impacts on their health and management of their disease. This survey highlights the need for allocation of additional supportive staff to help patients navigate the emerging obstacles to their care, both mental and physical. Policy decision-makers can help reduce care disruptions by establishing practices that allow for appropriate social distancing measures, ensuring sufficient supplies and equipment for staff, and communicating that the necessary steps have been taken for patients to safely resume or continue treatment plans without disruption. This includes fostering awareness of society guidelines, such as those from the American Society of Clinical Oncology, as discussed in an earlier edition of Altitudes.

Ground Level: The challenges of COVID-19 are amplified for cancer patients and their caregivers. Decisions such as whether to go to work, send their children to school, and whether to go to the clinic or hospital for appointments are an emerging source of anxiety. Many patients are feeling heightened financial strain with their copays and challenges with accessing personal protective equipment. Healthcare providers are now being asked to balance the safety and resources of this immunocompromised population with the need for timely treatment to control the growth and metastasis of their cancer. Multiple societies have issued guidance to aid in these decisions, as discussed in an earlier edition of Altitudes. Healthcare provider cancer network can support cancer patients by considering less burdensome therapies (in terms of immunosuppression, copays, and required office/infusion center visits) when possible, and by helping them seek additional support to reduce costs and copays and gain access to personal protective equipment.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.